Deutsche Bank Ag\ Crinetics Pharmaceuticals, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 216,117 shares of CRNX stock, worth $11.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

216,117

Previous 203,889 6.0%

Holding current value

$11.8 Million

Previous $9.13 Million 20.88%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$43.83 - $54.98 $535,953 - $672,295	12,228 Added 6.0%	216,117 $11 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $5.66 Million - $6.97 Million	134,282 Added 192.91%	203,889 $9.13 Million
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $376,103 - $506,484	-10,820 Reduced 13.45%	69,607 $3.26 Million
Q4 2023 Feb 14, 2024	BUY	$25.62 - $37.07 $1.29 Million - $1.86 Million	50,217 Added 166.23%	80,427 $2.86 Million
Q3 2023 Nov 09, 2023	BUY	$15.97 - $30.59 $113,786 - $217,953	7,125 Added 30.86%	30,210 $898,000
Q2 2023 Aug 14, 2023	SELL	$15.73 - $23.6 $239,630 - $359,522	-15,234 Reduced 39.76%	23,085 $415,000
Q1 2023 May 15, 2023	BUY	$15.31 - $21.1 $138,739 - $191,208	9,062 Added 30.97%	38,319 $615,000
Q4 2022 Feb 13, 2023	BUY	$15.49 - $19.05 $119,830 - $147,370	7,736 Added 35.95%	29,257 $535,000
Q3 2022 Nov 14, 2022	SELL	$18.11 - $22.37 $62,334 - $76,997	-3,442 Reduced 13.79%	21,521 $423,000
Q2 2022 Aug 11, 2022	SELL	$16.49 - $27.64 $21,931 - $36,761	-1,330 Reduced 5.06%	24,963 $466,000
Q1 2022 May 13, 2022	SELL	$17.15 - $28.31 $51,072 - $84,307	-2,978 Reduced 10.17%	26,293 $577,000
Q4 2021 Feb 11, 2022	SELL	$19.35 - $28.41 $1.18 Million - $1.73 Million	-60,785 Reduced 67.5%	29,271 $832,000
Q3 2021 Nov 04, 2021	BUY	$16.88 - $25.23 $16,373 - $24,473	970 Added 1.09%	90,056 $1.9 Million
Q2 2021 Aug 11, 2021	BUY	$15.9 - $21.15 $65,508 - $87,138	4,120 Added 4.85%	89,086 $1.68 Million
Q1 2021 May 13, 2021	BUY	$13.3 - $17.55 $857,783 - $1.13 Million	64,495 Added 315.06%	84,966 $1.3 Million
Q4 2020 Feb 16, 2021	BUY	$12.08 - $17.46 $60,931 - $88,068	5,044 Added 32.7%	20,471 $289,000
Q3 2020 Nov 12, 2020	BUY	$13.62 - $17.66 $17,787 - $23,063	1,306 Added 9.25%	15,427 $242,000
Q2 2020 Aug 13, 2020	BUY	$13.04 - $23.23 $134,611 - $239,803	10,323 Added 271.8%	14,121 $247,000
Q1 2020 May 14, 2020	SELL	$11.52 - $26.46 $2,557 - $5,874	-222 Reduced 5.52%	3,798 $56,000
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $14,005 - $23,057	919 Added 29.64%	4,020 $100,000
Q3 2019 Nov 14, 2019	SELL	$14.91 - $25.01 $2,639 - $4,426	-177 Reduced 5.4%	3,101 $45,000
Q2 2019 Aug 14, 2019	SELL	$21.48 - $27.71 $130,340 - $168,144	-6,068 Reduced 64.93%	3,278 $81,000
Q1 2019 May 15, 2019	BUY	$21.07 - $29.31 $52,675 - $73,275	2,500 Added 36.52%	9,346 $210,000
Q4 2018 Feb 14, 2019	SELL	$22.4 - $35.39 $199,673 - $315,466	-8,914 Reduced 56.56%	6,846 $203,000
Q3 2018 Dec 21, 2021	BUY	$22.66 - $36.8 $41,626 - $67,601	1,837 Added 13.19%	15,760 $451,000
Q3 2018 Nov 14, 2018	BUY	$22.66 - $36.8 $315,495 - $512,366	13,923 New	13,923 $397,000

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.6M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.94B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account